Vera Therapeutics Inc (NASDAQ:VERA) Price Forecast For The Next 12 Months Is Set At 38.

IPW

In last trading session, Vera Therapeutics Inc (NASDAQ:VERA) saw 0.34 million shares changing hands with its beta currently measuring 1.07. Company’s recent per share price level of $51.00 trading at $2.17 or 4.44% at ring of the bell on the day assigns it a market valuation of $3.23B. That closing price of VERA’s stock is at a discount of -1.2% from its 52-week high price of $51.61 and is indicating a premium of 75.33% from its 52-week low price of $12.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.6 million shares which gives us an average trading volume of 757.89K if we extend that period to 3-months.

For Vera Therapeutics Inc (VERA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Vera Therapeutics Inc (NASDAQ:VERA) trade information

Upright in the green during last session for gaining 4.44%, in the last five days VERA remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $51.00 price level, subtracting -1.76% to its value on the day. Vera Therapeutics Inc’s shares saw a change of 231.60% in year-to-date performance and have moved 8.44% in past 5-day. Vera Therapeutics Inc (NASDAQ:VERA) showed a performance of 25.49% in past 30-days. Number of shares sold short was 6.55 million shares which calculate 6.28 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 34 to the stock, which implies a fall of -50.0% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 38. It follows that stock’s current price would jump 88.24% in reaching the projected high whereas dropping to the targeted low would mean a gain of 88.24% for stock’s current value.

Vera Therapeutics Inc (VERA) estimates and forecasts

Statistics highlight that Vera Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 34.25% of value to its shares in past 6 months, showing an annual growth rate of -28.44% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.22% during past 5 years.

Vera Therapeutics Inc (NASDAQ:VERA)’s Major holders

Insiders are in possession of 6.83% of company’s total shares while institution are holding 94.71 percent of that, with stock having share float percentage of 101.65%. Investors also watch the number of corporate investors in a company very closely, which is 94.71% institutions for Vera Therapeutics Inc that are currently holding shares of the company. AVORO CAPITAL ADVISORS LLC is the top institutional holder at VERA for having 4.31 million shares of worth $155.92 million. And as of 2024-06-30, it was holding 8.4548 of the company’s outstanding shares.

The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 3.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.1022 of outstanding shares, having a total worth of $130.98 million.